GlassScriptPhysician profile
Stephanie Schatz
NPI 1255748349
$5,723.34
in general payments reported to CMS, 2019-2025
35 companies · $1,062 in 2025
The $1,062 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,319 · 2022: $1,157 · 2023: $1,142 · 2024: $1,043 · 2025: $1,062.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,247.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,247.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,306.46 | 2021-2025 | |
| Novo Nordisk INC | $420.41 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $395.41 | 2022-2025 | Otezla, Repatha, Evenity |
| Lilly USA, LLC | $254.75 | 2021-2025 | Mounjaro, Trulicity, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $246.33 | 2021-2025 | Jardiance |
| Astellas Pharma US INC | $214.48 | 2021-2024 | Veozah |
| Astrazeneca Pharmaceuticals LP | $179.19 | 2021-2025 | Breztri, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $152.90 | 2021-2025 | |
| Pfizer INC. | $140.41 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $113.65 | 2021-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $102.21 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $99.87 | 2023-2025 | Xifaxan |
| Lundbeck LLC | $97.80 | 2022-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $85.02 | 2021-2023 | Belsomra, Steglatro, Vaxneuvance |
| Radius Health, INC. | $83.33 | 2024-2025 | Tymlos |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $71.97 | 2022-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $67.35 | 2023-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $66.27 | 2021-2022 | |
| Abbott Laboratories | $66.11 | 2021-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $63.34 | 2023-2024 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $60.15 | 2021-2024 | Xarelto |
| Edwards Lifesciences Corporation | $51.05 | 2022-2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Exact Sciences Corporation | $46.70 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Esperion Therapeutics, INC. | $43.72 | 2024-2025 | Nexletol |
| Viatris Specialty LLC | $40.49 | 2025 | Yupelri |
| Ironwood Pharmaceuticals, INC | $39.41 | 2023-2024 | Linzess |
| Axsome Therapeutics, INC. | $38.18 | 2024 | Auvelity |
| Sanofi-Aventis U.S. LLC | $36.60 | 2021 | |
| Phathom Pharmaceuticals, INC. | $35.30 | 2024-2025 | Voquezna |
| Biohaven Pharmaceuticals, INC. | $27.60 | 2021 | |
| Antares Pharma, INC. | $17.92 | 2022 | |
| Valinor Pharma, LLC | $15.96 | 2023 | Movantik |
| Xeris Pharmaceuticals, INC. | $15.81 | 2025 | Gvoke Hypopen |
| Organon LLC | $13.84 | 2024 | |
| Sumitomo Pharma America, INC. | $13.35 | 2024 | Aptiom |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Schatz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.